Drug-induced impairment of renal function

International Journal of Nephrology and Renovascular Disease

Volumn 7, Issue , 2014, Pages 457-468

  Pazhayattil, George Sunny ^a   Shirali, Anushree C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute kidney injury; Chemotherapy; Chronic kidney disease; Drug nephrotoxicity; NSAIDs

Indexed keywords

ACICLOVIR; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BISPHOSPHONIC ACID DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CISPLATIN; COTRIMOXAZOLE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FOSCARNET; GENTAMICIN; LEFLUNOMIDE; METHOTREXATE; NEOMYCIN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN DERIVATIVE; POLYMYXIN DERIVATIVE; SALAZOSULFAPYRIDINE; STREPTOMYCIN; SULFADIAZINE; TACROLIMUS; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ANALGESIC NEPHROPATHY; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CRYSTALLURIA; DISEASE PREDISPOSITION; DIURESIS; DOSE RESPONSE; DRESS SYNDROME; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FANCONI RENOTUBULAR SYNDROME; GRAM NEGATIVE INFECTION; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERNATREMIA; HYPERPHOSPHATEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY PAPILLA NECROSIS; KIDNEY TUBULE ACIDOSIS; KIDNEY TUBULE DISORDER; MEMBRANOUS GLOMERULONEPHRITIS; METABOLIC ACIDOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMAL CHANGE GLOMERULONEPHRITIS; MYCOSIS; NEPHROTOXICITY; OTOTOXICITY; PAIN; REVIEW; RISK FACTOR; SKIN INFECTION; SOLID TUMOR; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSPECIFIED SIDE EFFECT; UREMIA; VULNERABLE POPULATION;

EID: 84919330867     PISSN: None     EISSN: 11787058     Source Type: Journal    
DOI: 10.2147/IJNRD.S39747     Document Type: Review

References (106)

1. Mehta RL, Pascual MT, Soroko S, et al; Program to Improve Care in Acute Renal Disease. Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Kidney Int. 2004;66(4):1613–1621.
2. Uchino S, Kellum JA, Bellomo R, et al; Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294(7):813–818.
3. Waikar SS, Liu KD, Chertow GM. Diagnosis, epidemiology and outcomes of acute kidney injury. Clin J Am Soc Nephrol. 2008;3(3): 844–861.
4. Perazella MA. Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol. 2009;4(7):1275–1283.
5. Lee W, Kim RB. Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol. 2004;44:137–166.
6. Khrunin AV, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the effcacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J. 2010;10(1): 54–61.
7. Anders M W. Metabolism of drugs by the kidney. Kidney Int. 1980;18(5): 636–647.
8. Lucena MI, Andrade RJ, Cabello MR, Hidalgo R, Gonzalez-Correa JA, Sanchez de la Cuesta F. Aminoglycoside-associated nephrotoxicity in extrahepatic obstructive jaundice. J Hepatol. 1995;22(2):189–196.
9. Patzer L. Nephrotoxicity as a cause of acute kidney injury in children. Pediatr Nephrol. 2008;23(12):2159–2173.
10. Carmody JB, Charlton JR. Short-term gestation, long-term risk: prematurity and chronic kidney disease. Pediatrics. 2013;131(6): 1168–1179.
11. Zappitelli M, Selewski DT, Askenazi DJ. Nephrotoxic medication exposure and acute kidney injury in neonates. Neoreviews. 2012;13(7): e420–e427.
12. Walsh SA, Creamer D. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clin Exp Dermatol. 2011;36(1):6–11.
13. Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med. 2011;124(7):588–597.
14. Augusto J F, Sayegh J, Simon A, et al. A case of sulphasalazine-induced DRESS syndrome with delayed acute interstitial nephritis. Nephrol Dial Transplant. 2009;24(9):2940–2942.
15. Pinto B, Dhir V, Krishnan S, Nada R. Lefunomide-induced DRESS syndrome with renal involvement and vasculitis. Clin Rheumatol. 2013;32(5):689–693.
16. Picard D, Janela B, Descamps V, et al. Drug reaction with eosino-philia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med. 2010;2(46):46-62.
17. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106(5B):13S–24S.
18. Schneider V, Lévesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinfammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol. 2006;164(9):881–889.
19. Campbell WB, Gomez-Sanchez CE, Adams B V, Schmitz JM, Itskovitz HD. Attenuation of angiotensin II- and III-induced aldos-terone release by prostaglandin synthesis inhibitors. J Clin Invest. 1979;64(6):1552–1557.
20. Kramer HJ, Glänzer K, Düsing R. Role of prostaglandins in the regulation of renal water excretion. Kidney Int. 1981;19(6):851–859.
21. Walker RM, Brown RS, Stoff JS. Role of renal prostaglandins during antidiuresis and water diuresis in man. Kidney Int. 1982;21(2): 365–370.
22. Denton KM, Fennessy PA, Alcorn D, Anderson W P. Morphometric analysis of the actions of angiotensin II on renal arterioles and glomeruli. Am J Physiol. 1992;262(3 Pt 2):F367–F372.
23. Palmer B F. Renal dysfunction complicating the treatment of hypertension. N Engl J Med. 2002;347(16):1256–1261.
24. Fried LF, Emanuele N, Zhang JH, et al; VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892–1903.
25. Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int. 2011;79(1):33–45.
26. Martínez-Salgado C, López-Hernández FJ, López-Novoa JM. Glomerular nephrotoxicity of aminoglycosides. Toxicol Appl Pharmacol. 2007;223(1):86–98.
27. Houghton DC, English J, Bennett WM. Chronic tubulointerstitial nephritis and renal insuffciency associated with long-term “subthera-peutic” gentamicin. J Lab Clin Med. 1988;112(6):694–703.
28. Casteels-Van Daele M, Corbeel L, Van de Casseye W, Standaert L. Gentamicin-induced Fanconi syndrome. J Pediatr. 1980;97(3):507–508.
29. Fujiwara K, Shin M, Matsunaga H, Saita T, Larsson LI. Light-microscopic immunocytochemistry for gentamicin and its use for studying uptake of the drug in kidney. Antimicrob Agents Chemother. 2009;53(8):3302–3307.
30. Levin ML. Aminoglycoside nephrotoxicity: keys to prevention. J Crit Illn. 1994;9(10):911–912, 915.
31. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med. 1996; 124(8):717–725.
32. Kastrup J, Petersen P, Bartram R, Hansen JM. The effect of trimethoprim on serum creatinine. Br J Urol. 1985;57(3):265–268.
33. Roy MT, First MR, Myre SA, Cacini W. Effect of co-trimoxazole and sulfamethoxazole on serum creatinine in normal subjects. Ther Drug Monit. 1982;4(1):77–79.
34. Alappan R, Perazella MA, Buller GK. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med. 1996;124(3):316–320.
35. Perazella MA, Mahnensmith RL. Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose. Clin Nephrol. 1996;46(3):187–192.
36. Jick H, Derby LE. A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and cephalexin for uncommon serious drug toxicity. Pharmacotherapy. 1995;15(4):428–432.
37. Fraser TN, Avellaneda AA, Graviss EA, Musher DM. Acute kidney injury associated with trimethoprim/sulfamethoxazole. J Antimicrob Chemother. 2012;67(5):1271–1277.
38. Hein R, Brunkhorst R, Thon W F, Schedel I, Schmidt RE. Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases. Clinical Nephrol. 1993;39(5):254–256.
39. Simon DI, Brosius FC 3rd, Rothstein DM. Sulfadiazine crystalluria revisited. The treatment of Toxoplasma encephalitis in patients with acquired immunodefciency syndrome. Arch Intern Med. 1990;150(11): 2379–2384.
40. Htike NL, Santoro J, Gilbert B, Elfenbein IB, Teehan G. Biopsy-proven vancomycin-associated interstitial nephritis and acute tubular necrosis. Clin Exp Nephrol. 2012;16(2):320–324.
41. van Hal SJ, Paterson DL, Lodise T P. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 1 5 and 2 0 milligrams per liter. Antimicrob Agents Chemother. 2013;57(2):734–744.
42. Chow AW, Azar RM. Glycopeptides and nephrotoxicity. Intensive Care Med. 1994;20 Suppl 4:S23–S29.
43. Oktem F, Arslan MK, Ozguner F, et al. In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by erdosteine. Toxicology. 2005;215(3): 227–233.
44. Bird ST, Etminan M, Brophy JM, Hartzema AG, Delaney JAC. Risk of acute kidney injury associated with the use of fuoroquinolones. CMAJ. 2013;185(10):E475–E482.
45. Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R. Crystalluria and ciprofoxacin, influence of urinary pH and hydration. Chemotherapy. 1986;32(5):408–417.
46. Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G. Ciprofoxacin crystal nephropathy. Am J Kidney Dis. 2007;50(2):330–335.
47. Barza M. The nephrotoxicity of cephalosporins: an overview. J Infect Dis. 1978;137 Suppl:S60–S73.
48. Pill M W, O’Neill C V, Chapman MM, Singh AK. Suspected acute interstitial nephritis induced by piperacillin-tazobactam. Pharmacotherapy. 1997;17(1):166–169.
49. Justo JA, Bosso JA. Adverse reactions associated with systemic polymyxin therapy. Pharmacotherapy. Epub 2014 September 30.
50. Becker BN, Schulman G. Nephrotoxicity of antiviral therapies. Curr Opin Nephrol Hypertens. 1996;5(4):375–379.
51. Sawyer MH, Webb DE, Balow JE, Straus SE. Acyclovir-induced renal failure. Clinical course and histology. Am J Med. 1988;84(6): 1067–1071.
52. Deray G, Martinez F, Katlama C, et al. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol. 1989;9(4): 316–321.
53. Maurice-Estepa L, Daudon M, Katlama C, et al. Identification of crystals in kidneys of AIDS patients treated with foscarnet. Am J Kidney Dis. 1998;32(3):392–400.
54. Vela Moreno J, Pascual Catalán A, Ramos Paesa C, Arazo Garcés P, Aguirre Errasti JM. Tetany caused by foscarnet in a female patient with acquired immunodeficiency syndrome. An Med Interna. 1995;12(7): 358–359. Spanish.
55. Gearhart MO, Sorg TB. Foscarnet-induced severe hypomagnesemia and other electrolyte disorders. Ann Pharmacother. 1993;27(3): 285–289.
56. Zaidan M, Lescure FX, Brochériou I, et al. Tubulointerstitial neph-ropathies in HIV-infected patients over the past 15 years: a clinico-pathological study. Clin J Am Soc Nephrol. 2013;8(6):930–938.
57. Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D’Agati VD, Markowitz GS. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int. 2010;78(11):1171–1177.
58. Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol. 2013;24(10):1519–1527.
59. Cooper RD, Tonelli M. Renal disease associated with antiretroviral therapy in the treatment of HIV. Nephron Clin Pract. 2011;118(3): c262–c268.
60. Kalyesubula R, Perazella MA. Nephrotoxicity of HAART. AIDS Res Treat. 2011;2011:562790.
61. Mistro S, Maciel Ide M, de Menezes RG, Maia Z P, Schooley RT, Badaró R. Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis. Clin Infect Dis. 2012;54(12): 1774–1777.
62. Heyman SN, Stillman IE, Brezis M, Epstein FH, Spokes K, Rosen S. Chronic amphotericin nephropathy: morphometric, electron microscopic, and functional studies. J Am Soc Nephrol. 1993;4(1):69–80.
63. Sawaya B P, Briggs J P, Schnermann J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol. 1995;6(2):154–164.
64. Ciarimboli G, Ludwig T, Lang D, et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005;167(6):1477–1484.
65. Miller R P, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins (Basel). 2010;2(11):2490–2518.
66. Pabla N, Murphy RF, Liu K, Dong Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol. 2009;296(3):F505–F511.
67. Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M; European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol. 2008;61(6):903–909.
68. Ciarimboli G, Holle SK, Vollenbröcker B, et al. New clues for nephro-toxicity induced by ifosfamide: preferential renal uptake via the human organic cation transporter 2. Mol Pharm. 2011;8(1):270–279.
69. Zamlauski-Tucker MJ, Morris ME, Springate JE. Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney. Toxicol Appl Pharmacol. 1994;129(1):170–175.
70. Widemann BC, Adamson PC. Understanding and managing methotrex-ate nephrotoxicity. Ooncologist. 2006;11(6):694–703.
71. Thierry FX, Vernier I, Dueymes JM, et al. Acute renal failure after high-dose methotrexate therapy. Role of hemodialysis and plasma exchange in methotrexate removal. Nephron. 1989;51(3):416–417.
72. Saland J, Leavey P, Bash R, Hansch E, Arbus G, Quigley R. Effective removal of methotrexate by high-fux hemodialysis. Pediatr Nephrol. 2002;17(10):825–829.
73. Buchen S, Ngampolo D, Melton RG, et al. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer. 2005;92(3):480–487.
74. Glezerman IG, Pietanza MC, Miller V, Seshan S V. Kidney tubular toxicity of maintenance pemetrexed therapy. Am J Kidney Dis. 2011;58(5):817–820.
75. Vootukuru V, Liew Y, Nally JV Jr. Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer. Med Oncol. 2006;23(3): 419–422.
76. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358(11): 1129–1136.
77. Muallem S, Moe OW. When EGF is offside, magnesium is wasted. J Clin Invest. 2007;117(8):2086–2089.
78. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int. 2008;74(11):1385–1393.
79. Kyle RA, Ye e GC, Somerfeld MR, et al; American Society of Clinical Oncology. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25(17):2464–2472.
80. Murphy S W, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol. 2000;11(1):177–182.
81. Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl. 2006(100):S11–S15.
82. Brar SS, Hiremath S, Dangas G, Mehran R, Brar SK, Leon MB. Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4(10):1584–1592.
83. ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced Nephropathy Trial (ACT). Circulation. 2011;124(11):1250–1259.
84. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343: 180–184.
85. Miner SE, Dzavik V, Nguyen-Ho P, et al. N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. Am Heart J. 2004;148:690–695.
86. Weisbord SD, Gallagher M, Kaufman J, et al. Prevention of contrast-induced AKI: a review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) Trial. Clin J Am Soc Nephrol. 2013;8(9):1618–1631.
87. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4(2):481–508.
88. Zarifan A, Meleg-Smith S, O’Donovan R, Tesi RJ, Batuman V. Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int. 1999;55(6):2457–2466.
89. Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RDM, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349(24):2326–2333.
90. Myers BD, Sibley R, Newton L, et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int. 1988;33(2): 590–600.
91. Marples D, Christensen S, Christensen EI, Ottosen PD, Nielsen S. Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla. J Clin Invest. 1995;95(4):1838–1845.
92. Markowitz GS, Radhakrishnan J, Kambham N, Valeri AM, Hines WH, D’Agati VD. Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. J Am Soc Nephrol. 2000;11(8):1439–1448.
93. Tam VK, Green J, Schwieger J, Cohen AH. Nephrotic syndrome and renal insuffciency associated with lithium therapy. Am J Kidney Dis. 1996;27(5):715–720.
94. Bendz H, Sjödin I, Toss G, Berglund K. Hyperparathyroidism and long-term lithium therapy – a cross-sectional study and the effect of lithium withdrawal. J Intern Med. 1996;240(6):357–365.
95. Brewster UC, Perazella MA. Proton pump inhibitors and the kidney: critical review. Clin Nephrol. 2007;68(2):65–72.
96. Simpson IJ, Marshall MR, Pilmore H, et al. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 1 5 cases. Nephrology (Carlton). 2006;11(5):381–385.
97. Blakely P, McDonald BR. Acute renal failure due to acetaminophen ingestion: a case report and review of the literature. J Am Soc Nephrol. 1995;6(1):48–53.
98. Jones AF, Vale JA. Paracetamol poisoning and the kidney. J Clin Pharm Ther. 1993;18(1):5–8.
99. Chapman MJ, Carrie A. Mechanisms of statin-induced myopathy: a role for the ubiquitin-proteasome pathway? Arterioscler Thromb Vasc Biol. 2005;25(12):2441–2444.
100. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292(21):2585–2590.
101. van Zyl-Smit R, Firth JC, Duffeld M, Marais AD. Renal tubular toxicity of HMG-CoA reductase inhibitors. Nephrol Dial Transplant. 2004;19(12):3176–3179.
102. Dickenmann M, Oettl T, Mihatsch MJ. Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis. 2008;51(3):491–503.
103. Clarkson MR, Giblin L, O’Connell F P, et al. Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol Dial Transplant. 2004;19(11):2778–2783.
104. González E, Gutiérrez E, Galeano C, et al; Grupo Madrileño De Nefritis Intersticiales. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int. 2008;73(8):940–946.
105. van Meer L, Moerland M, Cohen AF, Burggraaf J. Urinary kidney biomarkers for early detection of nephrotoxicity in clinical drug development. Br J Clin Pharmacol. 2014;77(6):947–957.
106. Vaidya VS, Ozer JS, Dieterle F, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol. 2010;28(5):478–485.